Different effects of two α-glucosidase inhibitors, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level

Journal of Diabetes and its Complications

Volumn 18, Issue 3, 2004, Pages 183-186

  Watanabe, Kenji ^a   Uchino, Hiroshi ^a   Ohmura, Chie ^a   Tanaka, Yasushi ^a   Onuma, Tomio ^a   Kawamori, Ryuzo ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Glucosidase inhibitors; 1,5 Anhydroglucitol; GC MS

Indexed keywords

1,5 ANHYDROSORBITOL; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; SULFONYLUREA; VOGLIBOSE;

ADULT; ALCOHOL BLOOD LEVEL; ANALYTICAL PARAMETERS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DIET THERAPY; DRUG EFFECT; FEMALE; GAS CHROMATOGRAPHY; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINALYSIS; URINARY EXCRETION;

ACARBOSE; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 2; FORECASTING; GLYCOSURIA; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INOSITOL; SERUM ALBUMIN; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 2442630514     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(03)00055-2     Document Type: Article

References (19)

1. 14C] acarbose to rats, dogs and man. Arzneimittel-Forschung. 39:1989;1254-1260
2. Akanuma Y., Morita M., Fukuzawa N., Yamanouchi T., Akanuma H. Urinary excretion of 1, 5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients. Diabetologia. 31:1988;831-835
3. Coniff R.F., Shapiro J.A., Seaton T.B. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Archives of Internal Medicine. 154:1994;2442-2448
4. Hillebrand I., Boehme K., Frank G., Fink H., Berchtold P. The effects of the α-glucosidase inhibitor BAY g 5421 (acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man. Research in Experimental Medicine (Berlin). 175:1979;81-86
5. Hotta N., Koh N., Sakakibara F., Naruse F., Yamada K., Takeuchi T., Yamada N., Fukasawa K., Kakuta H. Effect of acarbose on blood glucose profiles and plasma 1, 5-anhydro-D-glucitol in type 2 diabetes poorly controlled by sulfonylurea therapy. Biomedicine & Pharmacotherapy. 50:1996;297-302
6. Kelley D.E., Bidot P., Freedman Z., Haag B., Podlecki D., Rendell M., Schimel D., Weiss S., Taylor T., Krol A., Magner J. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care. 21:1998;2056-2061
7. Kishimoto M., Yamasaki Y., Kubota M., Arai K., Morishima T., Kawa-mori R., Kamada T. 1, 5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care. 18:1995;1156-1159
8. Leonhardt W., Hanefeld M., Fischer S., Schulze J. Efficacy of α-glucosidase inhibitors on lipid in NIDDM subjects hyperlipidaemia. European Journal of Clinical Investigation. 24:1994;45-49. Suppl
9. Matsumoto I., Kuhara T. A new chemical diagnostic method for inborn errors of metabolism by mass spectrometry - rapid, practical, and simultaneous urinary metabolites analysis. Mass Spectrometry Reviews. 15:1996;43-57
10. Matsumoto K., Yano M., Miyake S., Ueki Y., Yamaguchi Y., Akazawa S., Tominaga Y. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care. 21:1998;256-260
11. Sakane N., Yoshida T., Kogure A., Kondo M. Different effects of acarbose and voglibose on serum 1, 5-anhydroglucitol concentrations (letter). Diabetes Care. 21:1998;465-466
12. Servo C., Pitkanen E. Variation in polyol levels in cerebrospinal fluid and serum in diabetic patients. Diabetologia. 11:1975;575-580
13. Shinozaki K., Suzuki M., Ikebuchi M., Hirose J., Hara Y., Harano Y. Improvement of insulin sensitivity and dyslipidemia with a new α-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism. 45:1996;731-737
14. Shoemaker J.D., Elliot W.H. Automated screening of urine samples for carbohydrates, organic and amino acids after treatment with urease. Journal of Chromatography. 562:1991;125-138
15. Yamanouchi T., Akanuma Y. Serum 1, 5-anhydroglucitol (1, 5AG): new clinical marker for glycemic control. Diabetes Research and Clinical Practice. 24:1994;S261-S268. Supplement
16. Yamanouchi T., Minoda S., Yabuuchi M., Yabuuchi M., Akanuma Y., Akanuma H., Miyashita H., Akaoka I. Plasma 1, 5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes. 38:1989;723-729
17. Yamanouchi T., Ogata N., Tagaya T., Kawasaki T., Sekino N., Funato H., Akaoka L., Miyashita H. Clinical usefulness of serum 1, 5-anhydroglucitol in monitoring glycaemic control. Lancet. 347:1996;1514-1518
18. Yamanouchi T., Tachibana Y., Akanuma H., Minoda S., Shinohara T., Moromizato H., Miyashita H., Akaoka I. Origin and disposal of 1, 5-anhydroglucitol, a major polyol in the human body. American Journal of Physiology. 263:1992;E268-E273
19. Yoshioka K., Azukari K., Yoshida T., Kondo M. Rapid improvement of serum 1, 5-anhydroglucitol concentrations after administration of α-glucosidase inhibitor (letter). Diabetes Care. 20:1997;462